Use of metabolomics to elucidate the metabolic perturbation associated with hypertension in a black South African male cohort: the SABPA study

Deventer, C A van; Lindeque, Jeremie Zander; Rensburg, Peet Jansen van; Malan, Leoné; Westhuizen, Francois H. van der; Louw, R.

doi:10.1016/j.jash.2014.11.007

Cited by 33 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They identified three metabolic pathways including phenylalanine, tyrosine and tryptophan biosynthesis as well to be responsible for the observed changes in hypertension. A metabolomics study was also conducted in South Africa to investigate the underlying biological mechanisms responsible for increasing cases of hypertension associated with urbanization of the society especially among black male South Africans [36]. Urinary metabolomics profiles of 25 subjects with gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) revealed several metabolites changes that can be considered biomarkers of hypertension, CVD, abdominal adiposity, liver damage, inflammation and oxidative stress.…”

Section: Metabolites Profiling In Hypertension and Oxidative Stressmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics profiling in hypertension and blood pressure regulation: a review

Onuh

Aliani

2020

Clin Hypertens

View full text Add to dashboard Cite

Hypertension is a chronic health condition in which blood pressure is usually elevated beyond normal levels. It can progress with serious complications if left undetected and untreated. Incidence of hypertension is on the increase worldwide with debilitating consequences on the health systems of many countries. It is a multifactorial disorder that requires a multi-pronged approach to address it. One such approach is the use of metabolomics or metabolite profiling to understand its underlying cause and possibly control it. Changes in metabolites profiles have been used to accurately predict so many disease conditions in addition to identifying possible biomarkers and pathways associated in their pathogenicity. This will enable their early detection, diagnosis and treatment as well as likely complications that may arise and also assist in development of biomarkers for clinical uses. The objective of this review therefore is to present some of the current knowledge on the application of metabolomics profiling in hypertension and blood pressure control.

show abstract

Section: Metabolites Profiling In Hypertension and Oxidative Stressmentioning

confidence: 99%

“…Pathway analysis showed changes in ethanol metabolism. [ 36 ] 8. Hypertensive and normotensive Uygur patients 250 1 H-NMR of plasma metabolites OPLS-DA showed clear separation indicating differences between the two groups.…”

Section: Introductionmentioning

confidence: 99%

Metabolomics profiling in hypertension and blood pressure regulation: a review

Onuh

Aliani

2020

Clin Hypertens

View full text Add to dashboard Cite

show abstract

“…Gut microbiome composition is regulated jointly by the host genome, the colonic milieu and diet. 6 During digestion, gut microbes coproduce a wide range of metabolites such as short chain fatty acids (SCFAs), 8 lipopolysaccharide (LPS), 9 imidazole propionate, 10 among others, that are essential for regulating multiple host-microbiome pathways. 11 Previous studies in animals and humans have identified a gut microbiome signature of T2D.…”

Section: Introductionmentioning

confidence: 99%

Serum metabolites reflecting gut microbiome alpha diversity predict type 2 diabetes

et al. 2020

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is associated with reduced gut microbiome diversity, although the cause is unclear. Metabolites generated by gut microbes also appear to be causative factors in T2D. We therefore searched for serum metabolites predictive of gut microbiome diversity in 1018 females from TwinsUK with concurrent metabolomic profiling and microbiome composition. We generated a Microbial Metabolites Diversity (MMD) score of six circulating metabolites that explained over 18% of the variance in microbiome alpha diversity. Moreover, the MMD score was associated with a significantly lower odds of prevalent (OR[95%CI] = 0.22[0.07;0.70], P = .01) and incident T2D (HR [95%CI] = 0.31[0.11,0.90], P = .03). We replicated our results in 1522 individuals from the ARIC study (prevalent T2D: OR[95%CI] = 0.79[0.64,0.96], P = .02, incident T2D: HR[95%CI] = 0.87[0.79,0.95], P = .003). The MMD score mediated 28%[15%,94%] of the total effect of gut microbiome on T2D after adjusting for confounders. Metabolites predicting higher microbiome diversity included 3-phenylpropionate(hydrocinnamate), indolepropionate, cinnamoylglycine and 5-alpha-pregnan-3beta,20 alpha-diol monosulfate(2) of which indolepropionate and phenylpropionate have already been linked to lower incidence of T2D. Metabolites correlating with lower microbial diversity included glutarate and imidazole propionate, of which the latter has been implicated in insulin resistance. Our results suggest that the effect of gut microbiome diversity on T2D is largely mediated by microbial metabolites, which might be modifiable by diet.

show abstract

“…Metabolomics studies the metabolites resulting from biochemical degradation processes and allows conclusions to be drawn on the prevalence of such processes. Several studies highlighted distinctions in the metabolic footprint of patients with hypertension and hence the potential in its analysis (e.g., through gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry) [112][113][114]. One study pointed out that the metabolic perturbation associated with alcohol abuse may contribute to the development of hypertension, probably by a shift in the ratio of the oxidized:reduced forms of nicotinamide adenine dinucleotide (NADH:NAD + ) [112].…”

Section: Metabolomicsmentioning

confidence: 99%

“…Several studies highlighted distinctions in the metabolic footprint of patients with hypertension and hence the potential in its analysis (e.g., through gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry) [112][113][114]. One study pointed out that the metabolic perturbation associated with alcohol abuse may contribute to the development of hypertension, probably by a shift in the ratio of the oxidized:reduced forms of nicotinamide adenine dinucleotide (NADH:NAD + ) [112]. Other results suggest that disorders in amino acid metabolism might play an important role in the pathogenesis of juvenile hypertension and circulating levels of uridine adenosine tetraphosphate are strongly associated with the disease [113,115].…”

Section: Metabolomicsmentioning

confidence: 99%

Relevance of Personalized Health Care in Patients with Arterial Hypertension: Where are we now?

Binder¹,

Schäfer²,

Kaiser³

et al. 2016

Update on Essential Hypertension

View full text Add to dashboard Cite

Personalized health care (PHC) or precision medicine is a new medical concept that aids in treatment decisions for patients by tailoring them to their individual needs. It often employs genetic testing to select appropriate and optimal therapies (pharmacogenomics). Although this concept is widely applied in oncology, the field of hypertension is still in the early stages and "personalization" is currently limited to tailoring antihypertensive treatment according to age, comorbidities, and ethnicity. Despite the fact that incomplete/lack of treatment response occurs in 10-30% of hypertensive patients for angiotensin-converting enzyme (ACE) inhibitors and in 15-25% for β-blockers, major continental guidelines still recommend the use of antihypertensive agents in a "onesize-fits-all" approach, neglecting the 1977 postulation of the Joint National Committee that "all patients must receive individualized therapy programs." The arrival of molecular testing offers new possibilities to differentiate monogenetic from polygenetic disorders and to identify associations between hypertension and drug response to corresponding genes. Up to 50% of the variation in blood pressure (BP) is attributable to genetic factors. Polymorphisms have been identified and studied in genes for BPmodifying receptors, such as ADBR (β-adrenergic receptors), and pharmacological pathways (GNB3, RAAS system). Approximately, one-quarter of the currently analyzed gene polymorphisms demonstrate significant pharmacogenetic effects (ADD1 Gly460Trp and the insertion/deletion [I/D] polymorphism in intron 16 of the ACE gene). Several large screening studies are currently ongoing to assess the impact on efficacy of antihypertensive medication of variants in hypertension-susceptibility genes. The GenHAT substudy of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) assessed the predictive validity of the ACE I/D genotype for coronary heart disease. The Family Blood Pressure Program included 11,079 participants to map genetic variants associated with hypertension. In this review chapter, we display the current body of knowledge regarding PHC in the treatment of hypertension. In particular, we highlight genetic variants associated with hyperten

show abstract

Use of metabolomics to elucidate the metabolic perturbation associated with hypertension in a black South African male cohort: the SABPA study

Cited by 33 publications

References 54 publications

Metabolomics profiling in hypertension and blood pressure regulation: a review

Metabolomics profiling in hypertension and blood pressure regulation: a review

Serum metabolites reflecting gut microbiome alpha diversity predict type 2 diabetes

Relevance of Personalized Health Care in Patients with Arterial Hypertension: Where are we now?

Contact Info

Product

Resources

About